Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

被引：0
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Weiss, Jocelyn [1 ]
Bradstock, Ken
Bendall, Linda J.
机构：
[1] Westmead Hosp, Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1336
页数：1
相关论文
共 50 条
  • [21] mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    Teachey, David T.
    Sheen, Cecilia
    Hall, Junior
    Ryan, Theresa
    Brown, Valerie I.
    Fish, Jonathan
    Reid, Gregor S. D.
    Seif, Alix E.
    Norris, Robin
    Chang, Yueh J.
    Carroll, Martin
    Grupp, Stephan A.
    BLOOD, 2008, 112 (05) : 2020 - 2023
  • [22] Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
    Gazi, Mohiuddin
    Moharram, Sausan A.
    Marhall, Alissa
    Shah, Kinjal
    Kazi, Julhash U.
    CANCER RESEARCH, 2017, 77
  • [23] Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
    Venkatesan, Aranapakam M.
    Dehnhardt, Christoph M.
    Chen, Zecheng
    Delos Santos, Efren
    Dos Santos, Osvaldo
    Bursavich, Matthew
    Gilbert, Adam M.
    Ellingboe, John W.
    Ayral-Kaloustian, Semiramis
    Khafizova, Gulnaz
    Brooijmans, Natasja
    Mallon, Robert
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Yu, Ker
    Gibbons, Jay
    Abraham, Robert
    Mansour, Tarek S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 653 - 656
  • [24] Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR
    Yu, Tao
    Li, Ning
    Wu, Chengde
    Guan, Amy
    Li, Yi
    Peng, Zhengang
    He, Miao
    Li, Jie
    Gong, Zhen
    Huang, Lei
    Gao, Bo
    Hao, Dongling
    Sun, Jikui
    Pan, Yan
    Shen, Liang
    Chan, Chichung
    Lu, Xiulian
    Yuan, Hongyu
    Li, Yongguo
    Li, Jian
    Chen, Shuhui
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (03): : 256 - 261
  • [25] mTOR inhibitors are safe and effective radiosensitizers in glioblastoma Multiforme pre-clinical models
    Shinohara, E
    Niermann, CCK
    Mu, Y
    Zeng, F
    Hallahan, D
    Lu, B
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S172 - S173
  • [26] Novel imidazolopyrimidines as dual PI3-kinase/mTor inhibitors
    Dehnhardt, Christoph
    Venkatesan, Aranapakam
    Chen, Zecheng
    Delos Santos, Efren
    Santos, Oswaldo
    Bursavich, Matthew
    Brooijmans, Natasja
    Mallon, Robert
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Yu, Ker
    Ayral-Kaloustian, Semiramis
    Gibbons, Jay
    Abraham, Robert
    Mansour, Tarek
    CANCER RESEARCH, 2009, 69
  • [27] Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer
    Chen, Jiezhong
    CURRENT CANCER DRUG TARGETS, 2013, 13 (02) : 117 - 120
  • [28] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [29] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [30] REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS
    Klein-Goldberg, Anat
    Voloshin, Tali
    Zemer-Tov, Efrat
    Paz, Rom
    Koren, Lilach
    Wainer-Katsir, Kerem
    Volodin, Alexandra
    Koltun, Bella
    Brant, Boris
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2021, 23 : 84 - 84
12345